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ABSTRACT
A broad range of degenerative diseases is associated with intracellular inclusions formed by toxic, aggregation-prone mutant
proteins. Intranuclear inclusions constitute a pathological hallmark of oculopharyngeal muscular dystrophy (OPMD), a domi-
nantly inherited disease caused by (GCG) repeat expansions in the gene that encodes for nuclear poly(A) binding protein
(PABPN1). The mutation results in an extended polyalanine stretch that has been proposed to induce protein aggregation and
formation of intranuclear inclusions. Here we show that normal PABPN1 is inherently aggregation-prone when exogenously
expressed in either HeLa or myogenic C2 cells. Similar deposits of insoluble PABPN1 are formed by variant forms of the protein
containing either a polyalanine expansion or a complete deletion of the polyalanine tract, indicating that the mutation respon-
sible for OPMD is not essential for formation of PABPN1 inclusions. In contrast, interfering with any of the protein domains
required for stimulation of poly(A) polymerase prevents the formation of inclusions. Most surprisingly, photobleaching experi-
ments reveal that both normal and expanded PABPN1 molecules are not irreversibly sequestered into aggregates, but rather
move rapidly in and out of the inclusions. These findings have important implications for the interpretation of OPMD model
systems based on exogenous expression of PABPN1.
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INTRODUCTION
Many neurodegenerative diseases, including Alzheimer’s
disease, Parkinson’s disease, prion diseases, and Hunting-
ton’s disease, are characterized by intracellular aggregation
and deposition of pathogenic proteins (Taylor et al. 2002).
In the case of Huntington and other polyglutamine diseases,
a triplet repeat expansion gives rise to a mutant protein that
aggregates, forming inclusion bodies that are most fre-
quently localized in the nucleus of affected cells (for review,
see Zoghbi and Orr 2000; Bossy-Wetzel et al. 2004). Expan-
sion of a trinucleotide repeat is also the cause of oculopha-
ryngeal muscular dystrophy or OPMD (Brais et al. 1998), a
disease with poorly understood pathogenesis. The OPMD
expansion is translated into a polyalanine tract in the
nuclear poly(A) binding protein (PABPN1 or PABP2) and
because intranuclear inclusions containing PABPN1 repre-
sent a pathological hallmark of muscle cells from OPMD
patients, it has been suggested that the mutated PABPN1
induces or facilitates the formation of the inclusions
(Becher et al. 2000; Uyama et al. 2000; Fan et al. 2001; Bao
et al. 2002; Scheuermann et al. 2003).
PABPN1 is an abundant nuclear protein that stimulates
poly(A) polymerase (PAP) during polyadenylation of
mRNA precursors in metazoan cells (for a recent review, see
Kühn and Wahle 2004). Most eukaryotic messenger RNA
(mRNA) molecules have a long tract of adenosine nucleo-
tides at the 3 end, and this so-called poly(A) tail seems to
play a role in every step of the life of the mRNA. During or
shortly after gene transcription, mRNA precursors are
cleaved to form a new 3 end that receives a tail of ∼250
adenylate residues. Poly(A) addition is carried out by a
poly(A) polymerase enzyme that on its own is nearly inac-
tive (Wahle 1991a,b). In order to be active in polyadenyla-
tion, PAP depends on cleavage and polyadenylation speci-
ficity factor (CPSF), a complex of at least four polypeptides,
and PABPN1. CPSF and PABPN1 are thought to cooperate
in the stimulation of PAP by interacting with the enzyme
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and tethering it onto the RNA. In fact, PAP binds directly to
both the 160-kDa subunit of CPSF (Murthy and Manley
1995) and PABPN1, resulting in an increased affinity of the
enzyme for RNA (Kerwitz et al. 2003). PABPN1 is also
involved in controlling the length of the poly(A) to ∼250
nucleotides (Wahle 1991a, 1995; Bienroth et al. 1993) and
may additionally contribute to export of mRNA from the
nucleus to the cytoplasm (Chen et al. 1999; Calado et al.
2000a; Bear et al. 2003).
PABPN1 is a 306-amino-acid protein with a calculated
molecular mass of 32.8 kDa that is detected as a 49-kDa
polypeptide in SDS-PAGE (Nemeth et al. 1995). The pro-
tein contains a N-terminal domain that interacts with PAP
(Kerwitz et al. 2003), and two RNA binding domains re-
quired for binding to poly(A), a ribonucleoprotein-type
RNA binding domain located in the middle of the protein
sequence and a C-terminal domain rich in asymmetrically
dimethylated arginines (Smith et al. 1999; Kühn et al. 2003).
To gain insight into the mechanisms involved in forma-
tion of OPMD nuclear inclusions, we generated green fluo-
rescent protein (GFP) fusions with PABPN1 variants. The
fusion proteins were transiently expressed in human HeLa
cells and in the murine myogenic cell line, C2. The results
show that GFP-PABPN1 aggregation occurs in the absence
of polyalanine expansion. Propensity of GFP-PABPN1 to
form intranuclear inclusions is coupled to stimulation of
polyadenylation, and aggregation is a highly dynamic, re-
versible process.
RESULTS
Exogenous expression of normal PABPN1 induces
formation of insoluble nuclear inclusions enriched
in poly(A) RNA
Immunofluorescence microscopy using affinity-purified
antibodies reveals PABPN1 localized throughout the nu-
cleoplasm with higher concentration in speckles (Krause et
al. 1994). A similar distribution is observed when PABPN1
is fused to the green fluorescence protein (GFP-PABPN1)
and transiently expressed in HeLa cells (Fig. 1A, arrows).
However, ∼50% of the cells expressing GFP-PABPN1 show
additional intensely labeled foci or inclusion bodies in the
nucleus (Fig. 1A, arrowheads). Quantification of the ratio
between the mean fluorescence intensity in these foci and in
nuclear speckles indicates that GFP-PABPN1 is two- to five-
fold more concentrated in the inclusions. Brightly labeled
nuclear inclusions are also observed in cells expressing
PABPN1 tagged with a C-terminal hemaglutinin (HA) epi-
tope (Fig. 1B). It is therefore unlikely that formation of the
inclusions is an artifact caused by the large GFP tag. Similar
results were obtained upon transfection of the murine myo-
genic cell line C2 (Fig. 1C).
Since PABPN1 intranuclear inclusions constitute a
pathological hallmark of OPMD, we thought to compare
the properties of protein deposits produced by exogenous
expression of GFP-PABPN1 with those present in affected
muscle fibers from OPMD patients. We had previously
shown that OPMD nuclear inclusions accumulate poly(A)
RNA, ubiquitin, and proteasomes (Calado et al. 2000b). To
detect poly(A) RNA in cells expressing GFP-PABPN1, fluo-
rescence in situ hybridization was performed using an oli-
go(U) probe (Fig. 1D,G). In nontransfected cells, as well as
in cells that express GFP-PABPN1 but have no inclusions,
the oligo(U) probe labels the cytoplasm and the nucleus,
excluding the nucleolus. In cells that contain GFP-PABPN1
inclusions, these structures are intensely stained by the
probe (Fig. 1D,G, arrows). Labeling of the GFP-PABPN1
inclusions is totally abolished when hybridization with the
oligo(U) probe is performed in cells previously digested
with S7 (micrococcal) nuclease (Fig. 1E,H), a 3-OH end-
specific exoribonuclease that removes poly(A) tails (see
Calado and Carmo-Fonseca 2000). Thus, the inclusions are
highly enriched in poly(A) RNA. As PABPN1 binds tightly
to poly(A) (Wahle 1991a; Wahle et al. 1993), we incubated
cells with an oligo(A) probe (Fig. 1F,I). No specific labeling
is observed, suggesting that most of the GFP-PABPN1 pres-
FIGURE 1. Normal PABPN1 forms intranuclear inclusions enriched
in poly(A) RNA. HeLa (A,B) and C2 (C) cells were transfected with
either GFP-PABPN1 (A,C) or PABPN1-HA (B). A fraction of the cells
(∼50%) show GFP-PABPN1 distributed in the nucleoplasm with
higher concentration in speckles (A, arrows). Other cells show addi-
tional brightly labeled focal inclusions (A, arrowheads; B,C). HeLa
cells expressing GFP-PABPN1 were hybridized with either a poly(U)
probe (D,G; E,H) or a poly(A) probe (F,I). Arrows in panels(D,G)
point to PABPN1 inclusions. In panels(E,H), the cells were digested
with S7 nuclease before hybridization. Bar, 10 µm.
Intranuclear inclusions of PABPN1
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ent in the inclusions is associated with nuclear poly(A)
RNA.
Next, we tested whether the GFP-PABPN1 nuclear inclu-
sions contain insoluble protein and recruit proteasomes
(Fig. 2). As pathological OPMD inclusions are resistant to
salt extraction (Calado et al. 2000b), we treated HeLa cells
expressing GFP-PABPN1 with either 1 M KCl or 0.1% SDS.
As depicted in Figure 2A, the inclusions remain brightly
stained, whereas most of the fluorescence disappeared from
the nuclear speckles. In addition, HeLa cells expressing
GFP-PABPN1 were immunolabeled with antibodies di-
rected against 20S proteasomes and ubiquitin (Fig. 2B). As
previously described, HeLa cells contain nuclear foci,
termed clastosomes, that are enriched in
ubiquitin conjugates and the proteolyti-
cally active 20S core of the proteasome
(Lafarga et al. 2002). However, neither
ubiquitin nor proteasomes are detected
in the GFP-PABPN1 inclusions.
Viewed with the electron microscope,
the OPMD nuclear inclusions consist of
collections of tubular filaments ∼8.5 nm
in external diameter, disposed in tangles
or palisades decorated by anti-PABPN1
antibodies (Calado et al. 2000b). To un-
ambiguously determine the structure of
the inclusions induced by GFP-PABPN1
overexpression, immunoelectron mi-
croscopy was performed using anti-GFP
antibodies (Fig. 3). Although the gold
particles are predominantly associated
with amorphous material, a few scat-
tered tubular filaments with an external
diameter of ∼12 nm can be identified
(Fig. 3, arrows in a,b). Clearly, the GFP-
PABPN1 inclusions are much less orga-
nized at the ultrastructural level than
those observed in muscle cells from
OPMD patients.
Finally, we compared the aggregation
properties of wild-type GFP-PABPN1
with a mutant fusion protein containing
a polyalanine expansion. The normal
PABPN1 gene consists of a (GCG)6 re-
peat followed by (GCA)3(GCG). This
stretch codes for a homopolymer of ten
alanines. Although the most frequent
mutation responsible for OPMD is the
expansion from (GCG)6 to (GCG)9, pa-
tients containing up to (GCG)13 repeats
have been described (Brais et al. 1998).
We constructed a GFP-fusion plasmid
encoding a PABPN1 mutant with a
stretch of 17 alanines instead of 10
(GFP-PABPN1-ala17). C2 cells that ex-
press GFP-PABPN1-ala17 show either the characteristic dis-
tribution of endogenous PABPN1 throughout the nucleo-
plasm and nuclear speckles (Fig. 4A), or additional intensely
labeled nuclear inclusions (Fig. 4B). Similar results were
obtained in HeLa cells (Fig. 5A–C). Quantification of the
fluorescent signals (Fig. 5A–C) shows that the ratio be-
tween the mean fluorescence intensity in the nuclear inclu-
sions and in the nuclear speckles is similar in cells that
express either normal or mutant PABPN1. Furthermore, as
observed in cells expressing normal GFP-PABPN1, the
GFP-PABPN1-ala17 inclusions are enriched in poly(A)
RNA, are resistant to salt extraction, and fail to concentrate
ubiquitin or proteasomes (data not shown).
FIGURE 2. Normal PABPN1 forms insoluble inclusions that fail to recruit ubiquitin and
proteasomes. (A) HeLa cells expressing GFP-PABPN1 were treated with 1 M KCl or 0.1% SDS.
Note that GFP-PABPN1 is completely extracted from the nuclear speckles, whereas the protein
in focal inclusions is insoluble. (B) HeLa cells expressing GFP-PABPN1 were immunolabeled
with antibodies directed against 20S proteasomes and ubiquitin. Bar, 10 µm.
FIGURE 3. Inclusions formed by normal PABPN1 contain disorganized filaments. Thin sec-
tions of C2 cells expressing GFP-PABPN1 were immuno-gold labeled with anti-GFP antibody.
The inclusions are largely amorphous, but contain a few short filaments. Panels on the left
represent a high magnification of areas (a) and (b). Filaments are indicated by arrows (lon-
gitudinal section) and arrowheads (transverse section). Bar, 100 nm.
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In conclusion, our results indicate that exogenous expres-
sion of normal PABPN1 is sufficient to induce the forma-
tion of insoluble intranuclear inclusions that are highly en-
riched in poly(A) RNA. Moreover, expression of either
wild-type or expanded PABPN1 leads to the formation of
intranuclear inclusions with similar properties. Thus, ex-
pansion of the polyalanine homopolymer caused by the
OPMD mutation is not required to induce PABPN1 aggre-
gation in vivo.
Poly(A) polymerase is recruited to PABPN1 inclusions
Having shown that nuclear inclusions induced by exog-
enous expression of PABPN1 are enriched in poly(A) RNA,
we asked whether specific mRNAs are sequestered by these
structures. Fluorescence in situ hybrization (FISH) was
therefore performed using a probe to the abundant -actin
mRNA. Although fluorescent focal signals corresponding to
nascent -actin transcripts were observed in the nucleus, no
labeling was detected in the GFP-PABPN1 inclusions (Fig.
6A). Similar results were obtained using
a probe to detect the abundant GFP fu-
sion transcripts expressed in transfected
cells. Possible explanations for these
negative results could be that the local
concentration of actin or GFP-PABPN1
mRNAs in the inclusions is too low to
be detected by FISH, or that the inclu-
sions sequester a particular subset of
mRNAs. Alternatively, we may consider
that mRNAs are sequestered in the in-
clusions but are mostly degraded while
the poly(A) tails persist, or that the
poly(A) RNA present in the inclusions
does not correspond to mRNA.
To further investigate whether the
PABPN1 nuclear inclusions sequester
other proteins involved in mRNA bio-
genesis, HeLa cells expressing either
GFP-PABPN1 or GFP-PABPN1-ala17
were immunolabeled with antibodies
directed against hnRNP proteins, splicing factors, exon
junction complex proteins, 3-end processing factors, and
mRNA export factors (Fig. 6B). Antibodies directed against
hnRNP A1 and C proteins, splicing factor SC-35, exon
junction components REF and DEK, the export factor TAP
and the cytoplasmic poly(A) binding protein (PABPC)
failed to label either the GFP-PABPN1 or the GFP-
PABPN1-ala17 inclusions. Additionally, immunolabeling
experiments were performed with antibodies against the
cleavage and polyadenylation specificity factor subunits
CPSF-30, CPSF-70, CPSF-100, and CPSF-160, and the
cleavage stimulation factor subunit Cstf-50. Neither of these
proteins was detected in the GFP-PABPN1 or GFP-
PABPN1-ala17 inclusions. In contrast, an antibody specific
for poly(A) polymerase (PAP) reveals colocalization with
the aggregates (Fig. 7). In cells that do not contain GFP-
PABPN1 inclusions, PAP is uniformly distributed through-
out the nucleus and the cytoplasm (Fig. 7 A,E), whereas in
cells that show GFP-PABPN1 or GFP-PABPN1-ala17
nuclear inclusions, PAP appears enriched in these structures
(Fig. 7 B,F). The distribution of PAP is not altered in cells
that express a point mutant version of PABPN1 that does
not form inclusions in the nucleus (GFP-PABPN1-dm, see
below), indicating that anti-PAP antibodies are not cross-
reacting with the fusion protein (Fig. 7 C,G). Labeling of the
PABPN1 inclusions by anti-PAP antibodies resisted extrac-
tion with 1 M KCl, suggesting that PAP is tightly bound to
these structures (Fig. 7 D,H).
PABPN1 domains required for aggregation in vivo
To investigate how the structure of PABPN1 influences ag-
gregation and formation of nuclear inclusions, we generated
GFP fusions to mutant forms of the protein. For each mu-
FIGURE 5. Normal and expanded GFP-PABPN1 concentrate similarly in nuclear inclusions.
HeLa cells expressing wild-type GFP-PABPN1 (A,B) or GFP-PABPN1-ala17 (C). The graphs in
(A–C) correspond to a quantitative measurement of fluorescence intensity along the line
indicated in the images above. The average ratio between the fluorescence intensity in the
smallest visible nuclear inclusions and the surrounding nuclear speckles in cells expressing
normal or expanded GFP-PABPN1 is 1.8 and 1.9, respectively.
FIGURE 4. The distribution of expanded PABPN1 is similar to the
normal protein. C2 cells expressing GFP-PABPN1-ala17, a plasmid
that encodes a PABPN1 mutant with a stretch of 17 alanines instead of
10 (A,B). Bar, 10 µm.
Intranuclear inclusions of PABPN1
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tant, we analyzed HeLa cells with mean fluorescence inten-
sity similar to that of cells that do not contain GFP-
PABPN1 inclusions (Figs. 8, 9, low) and cells with mean
fluorescence intensity at least threefold higher (Figs. 8, 9,
high). Integrity of each fusion protein was confirmed by
Western blotting (Figs. 8, 9).
The primary structure of PABPN1 suggests a separation
into three domains (Kühn et al. 2003). The acidic N-termi-
nal domain includes the polyalanine homopolymer and is
essential for the stimulation of poly(A) polymerase. The
RNP-type domain, which extends from Met161 to Thr257 is
essential but not sufficient for poly(A) binding. The di-
methylated-arginine-rich C-terminal domain starts at
Asp258 and is required for full poly(A) affinity.
First, we studied the influence of the polyalanine homo-
polymer on PABPN1 aggregation. The panels in Figure 8A
depict cells expressing normal PABPN1, an expansion mu-
tant with a stretch of 17 alanines instead of 10 (GFP-
PABPN1-ala17), and a deletion mutant devoid of the ho-
mopolymer (GFP-PABPN1-ala). The three distinct pro-
tein variants show a similar nuclear distribution, i.e.,
concentration in nuclear speckles with additional accumu-
lation in nuclear inclusions. These results argue that the
N-terminal polyalanine stretch is dispensable for nuclear
inclusion formation.
To investigate the role of RNA binding in protein aggre-
gation (Fig. 8B), we analyzed cells expressing a PABPN1
variant containing two point mutations at Y175A and
F215A (GFP-PABPN1-dm), a combination of this form
with the alanine expansion (GFP-PABPN1-ala17dm) and a
complete C-terminal deletion mutant (GFP-PABPN1-
C49). The PABPN1-dm and PABPN1-C49 mutants have
strongly reduced binding to poly(A) (Kühn et al. 2003) and
are both defective in the stimulation of polyadenylation
(Kerwitz et al. 2003). In contrast to normal PABPN1, the
three mutants analyzed in Figure 8B remain uniformly dis-
tributed throughout the nucleoplasm. These mutant pro-
teins do not localize to nuclear speckles, do not form in-
clusions, and are completely solubilized when cells are ex-
tracted with 0.1% Triton-X100 prior to fixation.
In a phylogenetic comparison, the PABPN1 N-terminal
domain contains a highly conserved sequence of 30 amino
acids (L119-Q147) that is predicted to form an amphipathic
-helix or coiled-coil domain (Kerwitz et al. 2003; Kühn et
al. 2003). Expression of a series of PABPN1 variants with
deletion of residues 1–50 (GFP-PABPN1-N50), 1–65
(GFP-PABPN1-N65), and 1–113 (GFP-PABPN1-N113)
shows that all these mutants form intranuclear inclusions
(Fig. 9A; data not shown). In contrast, deletion of residues
1–160 (GFP-PABPN1-N160) prevents the formation of
inclusions (Fig. 9A). Expression of an additional variant
with deletion of residues 118–145 (GFP-PABPN1-118–
145) similarly fails to form inclusions, suggesting an in-
volvement of the putative -helix in PABPN1 aggregation
(Fig. 9A). To further investigate this idea, PABPN1 variants
containing point mutations in the predicted -helical do-
main were expressed as GFP fusion proteins and tested for
aggregation. The mutants L119A, A133S, and V143A have a
nuclear distribution similar to wild-type PABPN1. In con-
trast, an alanine substitution of L136, which abolishes
PABPN1 stimulation of poly(A) polymerase (Kerwitz et al.
2003), produces an uniform distribution of the protein
throughout the nucleoplasm (Fig. 9B). Although the vast
majority of cells expressing GFP-PABPN1-L136A are de-
void of intranuclear inclusions, 2%–5% of the cells do con-
tain aggregates.
Taken together these results suggest that formation of
PABPN1 inclusions is functionally coupled to polyadenyla-
tion.
FIGURE 6. PABPN1 inclusions do not sequester mRNA. (A) HeLa
cells expressing GFP-PABPN1 were hybridized with a probe specific
for -actin mRNA. Arrows point to nascent actin transcripts in the
nucleus. (B) HeLa cells expressing GFP-PABPN1 were immunolabeled
with antibodies against hnRNPA1, SC35, TAP, and CPSF-30. Bar,
10 µm.
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PABPN1 molecules in nuclear inclusions are
in constant exchange with the nucleoplasmic pool
Intracellular inclusions formed by aggregation-prone pro-
teins represent a hallmark of several degenerative diseases,
and one of the mechanisms proposed for toxicity of these
pathological inclusions is the sequestration of critical factors
by the aggregated protein (for review, see Taylor et al.
2002). The finding that many pathological inclusions are
highly insoluble further supports the view that abnormal
proteins are responsible for the formation of stable struc-
tures capable of trapping essential cellular components.
Similarly to pathological inclusions, the GFP-PABPN1 in-
clusions are resistant to detergent and high salt extraction.
We therefore expected that these structures correspond to
stable, static protein deposits in the nucleus. To directly
monitor the dynamics of PABPN1 interactions within the
inclusions, photobleaching analysis was performed in live
HeLa cells (Fig. 10). In photobleaching, a small region in
the nucleus is illuminated at high intensity by a high-pow-
ered focused laser beam. As a consequence, GFP molecules
present within that region are irreversibly bleached without
detectable damage to the cell. Subsequent diffusion of
bleached GFP molecules out of the bleached area and dif-
fusion of surrounding nonbleached GFP molecules into the
bleached area leads to a recovery of fluorescence, which is
recorded at low laser power. There are two variations of
photobleaching experiments that yield different types of in-
formation: fluorescence recovery after photobleaching
(FRAP), and fluorescence loss in photobleaching (FLIP). In
FRAP, a region is bleached once and subsequent recovery of
fluorescence in the bleached area is monitored over time. In
FLIP, a region is repeatedly bleached, and the loss of fluo-
rescence from the surrounding nonbleached area is moni-
tored over time (for review, see White and Stelzer 1999;
Reits and Neefjes 2001).
As depicted in Figure 10A, after bleaching of an entire
inclusion, GFP fluorescence from the nucleoplasmic pool
rapidly reassociated. Figure 10B shows the recovery of rela-
tive fluorescence intensity within the bleach region plotted
as a function of time. For comparison
purposes, we analyzed the kinetics of
wild-type GFP-PABPN1 and GFP-
PABPN1-ala17. For each GFP fusion
protein, the bleach area was selected to
contain either an inclusion or a nuclear
speckle. Similar kinetics were observed
for wild-type and mutant protein, both
in inclusions and in nuclear speckles.
Complete recovery occurs within 30 sec,
indicating that virtually the entire pool
of GFP-PABPN1 molecules has turned
over from either the inclusions or the
nuclear speckles during that period. In
contrast, a chimera formed by fusion of
PABPN1 with an amino-terminal fragment of the Cajal
body protein p80 coilin remains essentially immobile, as
previously described (Calapez et al. 2002).
To determine the dissociation kinetics of GFP-PABPN1
from the inclusions, we performed FLIP (Fig. 10C). By re-
peatedly bleaching a nucleoplasmic area, >95% of GFP
fluorescence was lost from all inclusion bodies. We there-
fore conclude that the pool of GFP-PABPN1 molecules in
the inclusions is continuously and rapidly exchanged with
the nucleoplasmic pool.
DISCUSSION
Here we show that normal PABPN1 tends to aggregate and
form intranuclear deposits when exogenously expressed in
either muscle or nonmuscle cells. Similarly to the intra-
nuclear inclusions present in affected muscle from OPMD
patients, the PABPN1 deposits are highly enriched in
poly(A) RNA and resist high-salt extraction. These deposits
are, however, much less organized at the ultrastructural
level than the disease inclusions and fail to concentrate
ubiquitin and proteasomes. Thus, exogenous expression of
PABPN1 mimics some, but not all, of the pathological fea-
tures detected in OPMD muscle biopsies.
Expression analysis of PABPN1 variants containing either
a polyalanine expansion or a complete deletion of the poly-
alanine tract, unambiguously demonstrates that expansion
of the polyalanine homopolymer caused by the OPMD mu-
tation is not required to induce PABPN1 aggregation and
formation of nuclear inclusions. In agreement with this ob-
servation, we had previously described the presence of fila-
mentous intranuclear inclusions composed of wild-type
PABPN1, poly(A) RNA, ubiquitin, and proteasomes in nor-
mal hypothalamic secretory neurons (Berciano et al. 2004).
The ubiquitin–proteasome system plays a key role in clear-
ing unwanted proteins from the cell, and its presence in
most disease-related inclusions most likely reflects a cellular
response to excess abnormal protein (for review, see Orr
2001). The proteasome is a multimeric enzyme composed
of two subcomplexes, the 20S proteolytic core and the 19S
FIGURE 7. PABPN1 inclusions recruit PAP. HeLa cells expressing wild-type GFP-PABPN1
(A,B,D) or GFP-PABPN1-dm (C) were immunolabeled with antibodies against poly(A) poly-
merase, PAP (E–H). In panels (D,H) the cells were extracted with 1 M KCl. Bar, 10 µm.
Intranuclear inclusions of PABPN1
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regulator. Protein substrates degraded by the proteasome
must first be marked by covalent ligation to ubiquitin in
order to become targeted for proteolysis (Bochtler et al.
1999). The finding that the inclusion bodies in secretory
neurons contain ubiquitin and proteasomes (Berciano et al.
2004) suggest that under some circumstances, deposition of
wild-type PABPN1 activates the cellular mechanism respon-
sible for disposal of abnormal proteins. In contrast, absence
of ubiquitin and proteasomes from the inclusions induced
by transient expression of wild-type PABPN1 may indicate
that formation of these deposits is entirely a passive mass-
action driven process with self-assembly of excess mono-
mers into a growing aggregate. In this regard it is interesting
to note that the smallest visible GFP-PABPN1 inclusions are
consistently observed in close proximity to nuclear speckles
(Fig. 5). As nuclear speckles contain the highest concentra-
tion of PABPN1 in normal nuclei, these compartments may
act as nucleation sites for protein aggregation.
A detailed analysis of deletion and point mutant variants
of PABPN1 shows that formation of intranuclear deposits is
tightly coupled to the stimulatory activity of the protein on
polyadenylation. In fact, an important role of PABPN1 in
the nucleus is to stimulate poly(A) polymerase (PAP) by
recruiting the enzyme to the substrate RNA (Kerwitz et al.
2003). Recruitment involves a direct interaction of PAP
with a coiled-coil structure within the N-terminal domain
FIGURE 9. Formation of PABPN1 inclusions requires the coiled-coil domain. HeLa cells were transfected with plasmids encoding PABPN1
variants fused to GFP. (A) HeLa cells expressing PABPN1 variants containing deletions of amino acids 1–113 (GFP-PABPN1-N113), 1–160
(GFP-PABPN1-N160) and 118–145 (GFP-PABPN1-118–145). For each PABPN1 variant, the upper panels depict cells with mean fluorescence
intensity similar to that of cells that do not contain GFP-PABPN1-wt inclusions (low) and cells with mean fluorescence intensity at least threefold
higher (high). Western blot analysis of each fusion protein is shown in lanes 1,2,3, respectively. Molecular weight markers (kDa) are indicated on
the left. (B) HeLa cells expressing PABPN1-ala17 substitution mutants L119A, A133S, L136A, and V143A (only cells with high fluorescence
intensity are shown). Bar, 10 µm. Western blot analysis of each fusion protein is shown in lanes 1,2,3, respectively, and molecular weight markers
(kDa) are indicated on the left.
FIGURE 8. Formation of PABPN1 inclusions requires binding to poly(A). HeLa cells were transfected with plasmids encoding PABPN1 variants
fused to GFP. For each PABPN1 variant, the upper panels depict cells with mean fluorescence intensity similar to that of cells that do not contain
GFP-PABPN1-wt inclusions (low) and cells with mean fluorescence intensity at least threefold higher (high). Bar, 10 µm. (A) HeLa cells expressing
normal PABPN1 (GFP-PABPN1-wt), an expansion mutant with a stretch of 17 alanines instead of 10 (GFP-PABPN1-ala17), and a deletion
mutant devoid of the homopolymer (GFP-PABPN1-ala). Western blot analysis of each fusion protein is shown in lanes 1,2,3, respectively.
Molecular weight markers (kDa) are indicated on the left. (B) HeLa cells expressing a PABPN1 variant containing two point mutations at Y175A
and F215A (GFP-PABPN1-dm), a combination of this form with the alanine expansion (GFP-PABPN1-ala17dm) and a complete C-terminal
deletion mutant (GFP-PABPN1-C49). Western blot analysis of each fusion protein is shown in lanes 1,2,3, respectively. Molecular weight
markers (kDa) are indicated on the left.
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of PABPN1. In addition, RNA allosterically activates the
interaction between the two proteins, and therefore the
stimulatory effect depends on binding to RNA. Physiologi-
cal binding of PABPN1 to poly(A) RNA requires both the
arginine-rich C-terminal domain, and a ribonucleoprotein-
type RNA binding domain (RNP domain) located approxi-
mately in the middle of the protein (Kühn et al. 2003).
Deletion of either the C-terminal domain of PABPN1 or
substitution of two essential amino acid residues in the RNP
domain completely abolishes aggregation. Likewise, dele-
tion of the 30 amino acid (L119-Q147) coiled-coil domain
or substitution of L136, which abolishes stimulation of
polyadenylation (Kerwitz et al. 2003), prevented formation
of PABPN1 insoluble deposits. Thus, interfering with any of
the PABPN1 domains involved in stimulation of polyade-
nylation abolishes formation of intranuclear inclusions.
In further agreement with the view that PABPN1 aggre-
gation is coupled to polyadenylation, the PABPN1 inclu-
sions are highly enriched in poly(A) RNA and PAP. The
inclusions are not labeled by an oligo(A) probe, arguing
that most, if not all, PABPN1 is associated with nuclear
poly(A) RNA. Intriguingly, no specific cellular mRNA or
proteins known to associate with mRNAs were detected
accumulated in the nucleus, raising the possibility that the
nuclear poly(A) enriched in the PABPN1 inclusions does
not correspond to mRNA. It is noteworthy that the nature
of poly(A) RNA present in nuclear speckles also remains
elusive (for review, see Lamond and Spector 2003). Assum-
ing that PABPN1 aggregates arise from nuclear speckles, it
is likely that speckles and inclusions may contain the same
type of poly(A) RNA.
Unexpectedly, the results from photobleaching experi-
ments indicate that PABPN1 molecules are not irreversibly
sequestered into aggregates, but rather move rapidly in and
out of the insoluble deposits. This finding clearly contrasts
with previous reports demonstrating that GFP fusions to
polyglutamine expansions localized to nuclear inclusions
are immobilized there (Chai et al. 2002; Kim et al. 2002).
FRAP and FLIP analysis of expanded polyglutamines (Kim
et al. 2002) or expanded polyglutamine proteins (Chai et al.
2002) reveal that these proteins have significantly reduced
mobility in the inclusions, whereas nonmutant forms of the
proteins do not aggregate. These studies further showed
immobilization of TBP and CBP present in the inclusions,
supporting a model of disease in which coaggregation and
sequestration of transcription factors contributes to patho-
genesis. Our FRAP and FLIP results reveal that both non-
expanded (wild-type) and expanded PABPN1 are highly
mobile proteins in the nucleus, irrespective of the presence
of nuclear inclusions. This lack of immobilization argues
that, despite being resistant to high-salt extraction, the
PABPN1 inclusions represent storage sites of concentrated
protein but not irreversible aggregates. A pool of polyglu-
tamine-expanded ataxin1 that rapidly exchanges between
nuclear inclusions and the nucleoplasm has also been de-
tected by photobleaching experiments (Stenoien et al.
2002). Thus, our results reinforce the view that not all
nuclear inclusions are necessarily static structures that could
contribute to pathogenesis by irreversibly trapping other
nuclear components.
At present we cannot determine in what extent the ob-
served GFP-PABPN1 aggregates reproduce the pathological
process that occurs in the nuclei of muscle cells from
OPMD patients. As OPMD cells containing nuclear inclu-
sions fail to grow in culture, current efforts are aimed at
constructing alternative model systems for this disease. By
FIGURE 10. PABPN1 molecules are not irreversibly sequestered into nuclear inclusions. (A) FRAP sequence of a HeLa cell expressing GFP-
PABPN1wt. The arrow indicates the bleached region. (B) FRAP kinetics of cells expressing GFP-PABPN1wt, GFP-PABPN1–17ala, and GFP-
PABPN1 fused to an N-terminal fragment of p80 coilin (amino acids 1–468). The bleached region contained either an aggregate (ag) or a nuclear
speckle (sp). The recovery curves correspond to a pool of three independent experiments, with 10 different cells analyzed per experiment. Error
bars represent standard deviations. D values represent mean ± SEM. (C) FLIP sequence of a HeLa cell expressing GFP-PABPN1wt. Repetitive
bleaching was performed in the area indicated by the arrow.
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providing a detailed characterization of the aggregation
properties of exogenously expressed PABPN1, our results
contribute a framework for improved design of OPMD
models.
MATERIALS AND METHODS
Cell culture, immunofluorescence,
and in situ hybridization
HeLa cells (derived from human cervical cancer) and C2 cells (an
established murine myogenic cell line derived from perinatal
mouse skeletal muscle) were used in this study.
HeLa and C2 cells were cultured as monolayers in Modified
Eagle’s Medium (MEM, Gibco Life Technologies) and Dulbecco’s
Modified Eagle’s Medium (DMEM, Gibco), respectively. MEM
was supplemented with 10% Fetal Calf Serum (FCS, Invitrogen)
and 1% nonessential amino acids (Gibco), whereas DMEM was
supplemented with 20% FCS.
Cells grown on 10 × 10 mm coverslips were briefly rinsed in
phosphate buffered saline (PBS) and fixed in 3.7% formaldehyde
(freshly prepared from paraformaldehyde) diluted in PBS for 10
min at room temperature. Cells were then permeabilized with
0.5% Triton X-100 in PBS for 10 min at room temperature. Al-
ternatively, cells were incubated with 0.1% Triton X-100 in CSK
buffer (100 mM NaCl, 300 mM sucrose, 10 mM PIPES, 3 mM
MgCl2, 1 mM EGTA, pH 6.8) for 5 min on ice prior to fixation.
Cells were additionally extracted with either 0.1% Triton X-100,
1M KCl in CSK buffer for 5 min on ice, or 0.1% SDS in HPEM
buffer (30 mM Hepes, 65 mM Pipes, 10 mM EGTA, 2 mM MgCl2,
pH 6.9) for 3 min at room temperature, followed by formaldehyde
fixation.
For immunofluorescence, cells were rinsed in PBS containing
0.05% Tween 20 (PBS-Tw), incubated for 1 hr with primary an-
tibodies diluted in PBS-Tw, washed with PBS-Tw and incubated
with appropriate secondary antibodies for 30 min. After washing
with PBS-Tw, the samples were mounted in VectaShield (Vector
Laboratories Inc.) and sealed with nail polish. Secondary antibod-
ies conjugated to FITC or Texas Red were obtained from Jackson
ImmunoResearch Laboratories. The following primary antibodies
were used in this study: monoclonal antibodies 4F4 and 9H10
against hnRNPC and hnRNP A1 proteins, respectively (Choi and
Dreyfuss 1984); monoclonal antibody against the cytoplasmic
poly(A)-binding protein, PABPC (Görlach et al. 1994); mono-
clonal antibody anti-SC35 (Fu and Maniatis 1990); monoclonal
antibodies against CPSF-160 and CPSF-100 (Jenny et al. 1994),
CstF-50 (Takagaki et al. 1990); rabbit polyclonal antibodies spe-
cific for poly(A) polymerase, CPSF-73, and CPSF-30 (Barabino et
al. 1997), TAP/NXF1 (Braun et al. 1999), REF (Rodrigues et al.
2001), and DEK (Fornerod et al. 1995). Proteasomes were detected
using polyclonal antibodies directed against the 20S catalytic core
(Arribas et al. 1994; Mengual et al. 1996) and ubiquitin-conjugates
were labeled with antibody Z0458 from DAKO. The hemaglutinin
epitope was detected with monoclonal antibody anti-HA from
COVANCE.
In situ hybridization to detect polyA RNA was performed as
previously described (Gama-Carvalho et al. 1997). In situ hybrid-
ization to detect -actin mRNA was performed using as probe, a
plasmid that contains full length -actin cDNA (Lennon et al.
1996). The plasmid was labeled with digoxigenin-11-dUTP (Roche
Biochemicals) by nick translation (Johnson et al. 1991) and hy-
bridization was performed according to Zirbel et al. (1993). Prior
to hybridization, cells were rinsed once in PBS, fixed in 3.7%
formaldehyde in PBS for 10 min at room temperature and per-
meabilized with 0.5% Triton X-100 and 0.5% Saponin in PBS for
10 min at room temperature. The cells were then incubated in a
2X SSC solution, at 37°C, for 5 min and the probe was added at a
final concentration of 10 ng/µl. Hybridization occurred overnight
at 37°C in a moist chamber. The probe was detected using Cy3
anti-Dig antibody (Jackson ImmunoReseach Laboratories).
Construction and expression of fusion proteins
The GFP-PABPN1-wt, GFP-PABPN1-dm, GFP-PABPN1-C49,
and GFP-PABPN1-N160 constructs, which contain the cDNA
encoding bovine PABPN1 subcloned in the pEGFP-C1 vector (BD
Biosciences Clontech), were previously described (Calado et al.
2000a). GFP-PABPN1-ala17, GFP-PABPN1-N113 and GFP-
PABPN1-ala were subcloned from the eukaryotic pGM10 ex-
pression vector (Smith et al. 1999) into pEGFP-C1. All the cDNAs
were initially cut with NdeI and the recessed 3 ends were filled in
with Klenow. The linear plasmid was then cut with BamHI and the
NdeI(filled)-BamHI fragment was purified. The pEGFP-C1 vector
was cut with SmaI and BamHI and ligated to the cDNA fragment.
The GFP-PABPN1-118–145 mutant was constructed as follows.
Using GFP-PABPN1-wt as template, we deleted the DNA stretch
comprised between nucleotides 352 and 435 by two PCR reactions
using primers GFP Fwd (CGAGAAGCGCGATCACATGGTCC)
and PABPN1 Rev (P-CGGGTCCTCAATGGCGCCGTC) for
PCR1 and primers GFP Rev (TTCAGGGGGAGGTGTGGGAGG
TT) and PABPN1 Fwd (P-CAGATGAATATGAGTCCACCTCCG)
for PCR2. The product obtained from PCR1 was subsequently
digested with EcoRI originating a 382-base pair fragment spanning
from the EcoRI site in the pEGFP polylinker to nucleotide 351 of
PABPN1. The product generated by PCR2 was digested with
BamHI to originate a 483-base-pair fragment spanning from
nucleotide 436 of PABPN1 to the BamHI site in the pEGFP
polylinker. The two PABPN1 fragments were then ligated to each
other and were inserted into EcoRI/BamHI digested pEGFP C1.
Plasmids containing point mutations in the coiled-coil domain of
PABPN1 have been described in Kerwitz et al. (2003). The plasmid
GFP-PABPN1-ala17 was digested in the unique XhoI site in the
PABPN1 coding sequence and in the BamHI site at the 3 end in
the polylinker. The original XhoI-BamHI fragment was then re-
placed by the corresponding XhoI-BamHI DNA fragments with
point mutations in the -helical domain of PABPN1. The same
procedure was used to construct the GFP-PABPN1-ala17dm fu-
sion. The GFP-PABPN1-N50 and GFP-PABPN1-N65 were
subcloned from pDNRLib into pEGFP-C3 with EcoRI and KpnI.
Additionally, a normal human PABPN1 cDNA was obtained
from the IMAGE. clone 4672226 and inserted in the pTRE2hyg
vector (Clontech) between the BamHI (filled in) and NheI (ligated
to XbaI) cloning sites. A C-terminal hemaglutinin (HA) epitope
was inserted by PCR using pTRE2hyg-PABPN1 as a template and
the primers HA Fwd (GAGCCGGGACTGGTCGAGGGTGACC
CG) and HA Rev (CGATCGATTTATGCATAATCAGGGACGTC
GTATGGGTACATTCCGTAAGGGGAATACC), which contain
restriction sites for BstEII and ClaI, respectively. The pTRE2hyg-
PABPN1 plasmid was cut in the BstEII unique site and in the ClaI
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site in the polylinker originating a fragment containing the 3
sequence of PABPN1 that was substituted by the digested PCR
product. Next, the PABPN1-HA cDNA was subcloned into
pcDNA3 vector using the KpnI and XhoI (ligated to SalI) restric-
tion sites in the polylinker.
All DNA constructs were verified by sequencing. Final DNA
plasmids were purified using the QIAGEN plasmid DNA midi kit.
Subconfluent HeLa and C2 cells were transfected using FuGENE6
(Roche Biochemicals) according to the manufacturer’s instruc-
tions. Cells were analyzed at 16–24 hr after transfection.
Fluorescence microscopy and photobleaching
Fluorescent samples were analyzed using the laser scanning mi-
croscope LSM 510 (Carl Zeiss). For quantitative analysis, images
were obtained from cells expressing normal or expanded GFP-
PABPN1 using the same acquisition settings. From each experi-
ment, average fluorescence intensities were estimated for 10 ran-
domly selected cells. FRAP and FLIP experiments were performed
as described (Calapez et al. 2002).
Immunoelectron microscopy
C2 cells expressing GFP-PABPN1 were fixed in formaldehyde and
embedded in Lowicryl K4 M as previously described (Lafarga et al.
2002). Ultrathin sections on gold grids were sequentially incubated
with anti-GFP antibody (Roche Biochemicals) and an appropriate
secondary antibody conjugated to 5-nm gold particles (BioCell).
The samples were examined with an EM208 electron microscope
(Philips, Eindhoven) operated at 60 kV.
SDS-PAGE and immunoblotting
SDS-PAGE and Western blotting were performed as previously
described (Almeida et al. 1998). Cells were washed twice in PBS,
mixed with SDS sample buffer and Benzonase endonuclease
(Sigma-Aldrich) and boiled. Proteins were separated by SDS-
PAGE on 10% polyacrylamide minigels (BioRad Laboratories) and
electroblotted to a nitrocelulose membrane. Membranes were
washed in PBS, blocked with PBS 5% low fat milk for at least 1 hr
and incubated with specific primary antibodies diluted in PBS
2.5% low fat milk at 4°C overnight. Membranes were then washed
3 × 15 min in PBS-Tw 2.5% low fat milk, incubated with appro-
priated secondary antibodies conjugated with horseradish peroxi-
dase (BioRad Laboratories) and developed using a chemilumines-
cence reaction (ECL; Amersham Buchler GmbH).
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